Prof. Yanmei Zou 邹燕梅
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of common cancers, including colorectal, gastric, lung, esophageal, liver, pancreatic, cervical, nasopharyngeal, breast cancer, lymphoma, and bone and soft tissue tumors.
Dr. Zou graduated from Tongji Medical College, Huazhong University of Science and Technology in 2002. From 2011 to 2012, Dr. Zou conducted tumor-related research at the Hormel Institute, Mayo Clinic, USA. With nearly 20 years of clinical experience, Dr. Zou has led or participated in multiple National Natural Science Foundation and provincial-level projects and published papers in SCI journals.
Professional roles
- Standing Committee Member, Tumor Precision Therapy Committee, Hubei Immunology Society
- Member, Tumor Nutrition and Metabolism Professional Committee, Hubei Anti-Cancer Association
- Member, Chinese Society of Clinical Oncology (CSCO)
- Member, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zou Yanmei). Papers usually list the name as Yanmei Zou or Zou Y.
Selected publications
35 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Rev Cancer, 2025 (senior author): Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope. PubMed 40516634
- Transl Lung Cancer Res, 2022 (first author): Multi-omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique sensitivity to first-line therapies. PubMed 36519025
- Front Immunol, 2021 (senior author): PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer. PubMed 34975854
- J Exp Clin Cancer Res, 2021 (senior author): PARP inhibitors in gastric cancer: beacon of hope. PubMed 34167572
- Front Oncol, 2021 (senior author): Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis. PubMed 33777744
- Biosci Rep, 2021 (senior author): Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer. PubMed 33345281
- Curr Med Sci, 2020 (senior author): Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis. PubMed 32166669
- Eur J Cell Biol, 2018 (first author): LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells. PubMed 29773344
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion